Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website https://www.thejh.org

Original Article

Volume 10, Number 1, February 2021, pages 1-7


A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Figures

Figure 1.
Figure 1. Overall survival for all patients. Survival was calculated from date of enrollment until date of death from any cause. VSLI: vincristine sulfate liposome injection.
Figure 2.
Figure 2. Time on therapy. Time on VSLI was calculated from time of first dose to time of discontinuation for any cause. VSLI: vincristine sulfate liposome injection.

Tables

Table 1. Patient Characteristics
 
CR1: first complete remission; HDAC: high-dose cytarabine (Ara-C); IDAC: intermediate-dose Ara-C.
Median age (range)78 (41 - 81)
Age ≥ 60 years old (%)4/5 (80%)
Male (%)3/5 (60%)
No. Caucasian (%)5/5 (100%)
ECOG performance status
  0 - 11/5 (20%)
  24/5 (80%)
  30 (0%)
Median duration of CR1 in months (range)3 (3 - 11)
Refractory disease (%)2/5 (40%)
Previous lines of salvage
  00 (0%)
  12/5 (40%)
  21/5 (20%)
> 22/5 (40%)
Antecedent hematologic disorder1/5 (20%)
Previous HDAC or IDAC-based salvage4/5 (80%)
ELN 2017 cytogenetic risk score
  Good risk0/5 (0%)
  Intermediate risk2/5 (40%)
  Poor risk3/5 (60%)
Median %blasts in marrow (range)29% (15-49%)

 

Table 2. Toxicities
 
Patient numberCycleToxicityGrade
011Abdominal pain2
011Bloating2
011Constipation2
011Peripheral sensory neuropathy1
012Abdominal distension2
021Constipation1
021Peripheral sensory neuropathy1
031Abdominal distension1
031Anorexia2
031Bloating1
031Constipation2
031Nausea2
031Peripheral sensory neuropathy1
031Vomiting1
041Abdominal pain2
041Nausea3
051Abdominal pain2
051Constipation1
051Nausea1
051Peripheral sensory neuropathy1
051Rash maculo-papular1